NOVAVAX Reports Positive Results From Phase I Trial of Respiratory Syncytial Virus Vaccine Candidate

Novavax, Inc. (Nasdaq: NVAX) today announced positive top-line results from a Phase I clinical study of its respiratory syncytial virus fusion recombinant nanoparticle vaccine candidate. In a paper titled "Recombinant RSV F nanoparticle vaccine for respiratory disease: antigen characterization, preclinical efficacy and clinical evaluation," Gregory M. Glenn, M.D., Senior Vice President and Chief Medical Officer of Novavax, is presenting safety, immunogenicity and tolerability findings from this study in a poster and oral presentation today and tomorrow, respectively, at the 5^th Vaccine and ISV Annual Global Conference in Seattle.